Develops drugs for rheumatoid arthritis and psoriasis.
Dec 2025Revenue $405K/yrExpenses $10.4M/yr
No trendCash runway ≈ 7 months from Dec 2025
Figures by year
When will Can-Fite BioPharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $405K and expenses $10.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $405K | $10.4M | −$9.95M |
| Dec 2024 | $674K | $8.80M | −$8.13M |
| Dec 2023 | $743K | $8.94M | −$8.20M |
| Dec 2022 | $810K | $10.9M | −$10.1M |
| Dec 2021 | $853K | $13.7M | −$12.8M |
| Dec 2020 | $763K | $14.9M | −$14.1M |
| Dec 2019 | $2.03M | $14.0M | −$12.0M |
| Dec 2018 | $3.82M | $9.23M | −$5.41M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.